Department of Neurology, Columbia University Irving Medical Center, New York, NY.
Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Ann Neurol. 2024 Dec;96(6):1209-1224. doi: 10.1002/ana.27071. Epub 2024 Sep 4.
Mitochondrial DNA (mtDNA) depletion/deletions syndrome (MDDS) comprises a group of diseases caused by primary autosomal defects of mtDNA maintenance. Our objective was to study the etiology of MDDS in 4 patients who lack pathogenic variants in known genetic causes.
Whole exome sequencing of the probands was performed to identify pathogenic variants. We validated the mitochondrial defect by analyzing mtDNA, mitochondrial dNTP pools, respiratory chain activities, and GUK1 activity. To confirm pathogenicity of GUK1 deficiency, we expressed 2 GUK1 isoforms in patient cells.
We identified biallelic GUK1 pathogenic variants in all 4 probands who presented with ptosis, ophthalmoparesis, and myopathic proximal limb weakness, as well as variable hepatopathy and altered T-lymphocyte profiles. Muscle biopsies from all probands showed mtDNA depletion, deletions, or both, as well as reduced activities of mitochondrial respiratory chain enzymes. GUK1 encodes guanylate kinase, originally identified as a cytosolic enzyme. Long and short isoforms of GUK1 exist. We observed that the long isoform is intramitochondrial and the short is cytosolic. In probands' fibroblasts, we noted decreased GUK1 activity causing unbalanced mitochondrial dNTP pools and mtDNA depletion in both replicating and quiescent fibroblasts indicating that GUK1 deficiency impairs de novo and salvage nucleotide pathways. Proband fibroblasts treated with deoxyguanosine and/or forodesine, a purine phosphatase inhibitor, ameliorated mtDNA depletion, indicating potential pharmacological therapies.
Primary GUK1 deficiency is a new and potentially treatable cause of MDDS. The cytosolic isoform of GUK1 may contribute to the T-lymphocyte abnormality, which has not been observed in other MDDS disorders. ANN NEUROL 2024;96:1209-1224.
线粒体 DNA(mtDNA)耗竭/缺失综合征(MDDS)由一组因 mtDNA 维持的原发性常染色体缺陷引起的疾病组成。我们的目的是研究 4 名缺乏已知遗传病因致病性变异的 MDDS 患者的病因。
对先证者进行全外显子组测序以鉴定致病性变异。我们通过分析 mtDNA、线粒体 dNTP 池、呼吸链活性和 GUK1 活性来验证线粒体缺陷。为了确认 GUK1 缺乏的致病性,我们在患者细胞中表达了 2 种 GUK1 同工型。
我们在所有 4 名先证者中发现了 GUK1 的双等位致病性变异,他们表现为上睑下垂、眼肌麻痹和肌病性近端肢体无力,以及可变的肝病史和改变的 T 淋巴细胞谱。所有先证者的肌肉活检均显示 mtDNA 耗竭、缺失或两者兼有,以及线粒体呼吸链酶活性降低。GUK1 编码鸟苷酸激酶,最初被鉴定为细胞质酶。GUK1 存在长和短同工型。我们观察到长同工型是线粒体内的,短同工型是细胞质的。在先证者的成纤维细胞中,我们注意到 GUK1 活性降低导致线粒体 dNTP 池失衡,以及增殖和静止成纤维细胞中的 mtDNA 耗竭,表明 GUK1 缺乏会损害从头和补救核苷酸途径。用脱氧鸟苷和/或嘌呤磷酸酶抑制剂氟达拉滨处理先证者的成纤维细胞可改善 mtDNA 耗竭,表明可能有潜在的药物治疗方法。
原发性 GUK1 缺乏是 MDDS 的一种新的、潜在可治疗的原因。细胞质同工型的 GUK1 可能导致未在其他 MDDS 疾病中观察到的 T 淋巴细胞异常。神经病学年鉴 2024;96:1209-1224.